{"title":"Action4Diabetes:一个在东南亚弥合1型糖尿病鸿沟的非营利性组织","authors":"Sze May Ng","doi":"10.1002/pdi.2463","DOIUrl":null,"url":null,"abstract":"Global incidence and challenges of type 1 diabetes Type 1 diabetes (T1D) is a chronic disease that affects millions of people around the world. The International Diabetes Federation (IDF) reports that the global incidence of T1D is estimated to be around 15 cases per 100,000 population per year.1 There has been a global increase in the incidence of T1D over the past few decades, particularly in children under the age of five. The reasons for this increase in incidence are not well understood, but it is thought to be due to a combination of genetic and environmental factors. In the UK, around 400,000 people are affected by T1D and life expectancy is reduced in people with T1D.2 Diabetes remains a leading cause of blindness in people of working age, the leading cause of renal failure and second most common cause of lower limb amputation. While the condition can be managed with proper treatment and care, those living in low-middle income countries (LMICs) often lack access to the necessary resources, resulting in poor health outcomes for many living with T1D.1 In LMICs, T1D is often diagnosed late due to limited access to health care services and diagnostic tools. This delay in diagnosis can result in high mortality rates from diabetic ketoacidosis (DKA). Once diagnosed, managing T1D in LMICs can be a challenge. The cost of insulin and other medications can be prohibitively expensive, and many people do not have access to blood glucose monitoring devices, blood glucose strips or other essential diabetes supplies. As a result, many people with T1D in these countries must rely on inadequate treatment options putting their health at risk of lifelong complications such as nerve damage, blindness, and kidney failure.3","PeriodicalId":20309,"journal":{"name":"Practical Diabetes","volume":"51 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Action4Diabetes: a non‐profit organisation bridging the type 1 diabetes gap in Southeast Asia\",\"authors\":\"Sze May Ng\",\"doi\":\"10.1002/pdi.2463\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Global incidence and challenges of type 1 diabetes Type 1 diabetes (T1D) is a chronic disease that affects millions of people around the world. The International Diabetes Federation (IDF) reports that the global incidence of T1D is estimated to be around 15 cases per 100,000 population per year.1 There has been a global increase in the incidence of T1D over the past few decades, particularly in children under the age of five. The reasons for this increase in incidence are not well understood, but it is thought to be due to a combination of genetic and environmental factors. In the UK, around 400,000 people are affected by T1D and life expectancy is reduced in people with T1D.2 Diabetes remains a leading cause of blindness in people of working age, the leading cause of renal failure and second most common cause of lower limb amputation. While the condition can be managed with proper treatment and care, those living in low-middle income countries (LMICs) often lack access to the necessary resources, resulting in poor health outcomes for many living with T1D.1 In LMICs, T1D is often diagnosed late due to limited access to health care services and diagnostic tools. This delay in diagnosis can result in high mortality rates from diabetic ketoacidosis (DKA). Once diagnosed, managing T1D in LMICs can be a challenge. The cost of insulin and other medications can be prohibitively expensive, and many people do not have access to blood glucose monitoring devices, blood glucose strips or other essential diabetes supplies. As a result, many people with T1D in these countries must rely on inadequate treatment options putting their health at risk of lifelong complications such as nerve damage, blindness, and kidney failure.3\",\"PeriodicalId\":20309,\"journal\":{\"name\":\"Practical Diabetes\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Practical Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pdi.2463\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Practical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pdi.2463","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Action4Diabetes: a non‐profit organisation bridging the type 1 diabetes gap in Southeast Asia
Global incidence and challenges of type 1 diabetes Type 1 diabetes (T1D) is a chronic disease that affects millions of people around the world. The International Diabetes Federation (IDF) reports that the global incidence of T1D is estimated to be around 15 cases per 100,000 population per year.1 There has been a global increase in the incidence of T1D over the past few decades, particularly in children under the age of five. The reasons for this increase in incidence are not well understood, but it is thought to be due to a combination of genetic and environmental factors. In the UK, around 400,000 people are affected by T1D and life expectancy is reduced in people with T1D.2 Diabetes remains a leading cause of blindness in people of working age, the leading cause of renal failure and second most common cause of lower limb amputation. While the condition can be managed with proper treatment and care, those living in low-middle income countries (LMICs) often lack access to the necessary resources, resulting in poor health outcomes for many living with T1D.1 In LMICs, T1D is often diagnosed late due to limited access to health care services and diagnostic tools. This delay in diagnosis can result in high mortality rates from diabetic ketoacidosis (DKA). Once diagnosed, managing T1D in LMICs can be a challenge. The cost of insulin and other medications can be prohibitively expensive, and many people do not have access to blood glucose monitoring devices, blood glucose strips or other essential diabetes supplies. As a result, many people with T1D in these countries must rely on inadequate treatment options putting their health at risk of lifelong complications such as nerve damage, blindness, and kidney failure.3
期刊介绍:
Practical Diabetes concerns itself with all aspects of the worldwide clinical science and practice of diabetes medicine. The journal recognises the importance of each member of the healthcare team in the delivery of diabetes care, and reflects this diversity of professional interest in its editorial contents. The Editors welcome original papers, case reports, practice points, audit articles and letters on any aspect of clinical diabetes care from any part of the world. The journal also publishes commissioned leaders, review articles and educational and training series, for which an honorarium normally is paid. All articles submitted to Practical Diabetes are independently peer reviewed. They must not have been published or be under submission currently elsewhere. Enquiries from prospective authors are welcomed and the Editors will be pleased, if asked, to advise on preparation and submission of articles. All articles and enquiries should be directed to the Editors at the publishing address below. The journal is published nine times a year, and currently the average waiting time for acceptance of articles is eight weeks, and for subsequent publication sixteen weeks. Practical Diabetes is independent of any commercial or vested interest.